Advanced age raises mortality risk in metastatic prostate cancer. Learn how PSA, tumour grade, and treatment influence ...

Agency staff expressed uncertainty over whether PFS benefit was "clinically meaningful" ...

An FDA advisory committee voted 7-1 to recommend expanding capivasertib use to treat PTEN-deficient metastatic hormone-sensitive prostate cancer, citing improved progression-free survival in a phase ...

The US Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) has recognized a favorable benefit risk profile for AstraZeneca’s TRUQAP® (capivasertib) in combination with ...

Convergent Therapeutics Inc., a clinical-stage biotechnology company developing next-generation alpha-emitting radioantibodies for the treatment of advanced prostate cancer, today announced that ...

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the first patient has been dosed in one of three expansion cohorts in the Phase 1 trial evaluating VIR-5500, a prostate-specific membrane ...

TLX597-Tx is a PSMA1-targeting small molecule radioligand therapy (RLT) candidate, designed to improve quality-of-life and efficacy in ...

Although it reads like European license plate number, a protein known as ZMYND8 has demonstrated its ability to block metastasis-linked genes in prostate cancer, according to a study at The University ...

An FDA advisory committee has recommended expanding AstraZeneca’s capivasertib for use with abiraterone and prednisone in PTEN-deficient metastatic hormone-sensitive prostate cancer. The 7-1 vote, ...